Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan
Abstract Breast cancer is the fifth leading cause of cancer death globally. In this retrospective study, we investigated the effects of the diagnosis-to-first-treatment interval (DFTI) and other related factors on cancer-specific survival in patients with breast cancer. We included 49,426 patients n...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-23683-y |
| _version_ | 1797988501908619264 |
|---|---|
| author | Nai-Chen Shih Pei-Tseng Kung Wei-Yin Kuo Wen-Chen Tsai |
| author_facet | Nai-Chen Shih Pei-Tseng Kung Wei-Yin Kuo Wen-Chen Tsai |
| author_sort | Nai-Chen Shih |
| collection | DOAJ |
| description | Abstract Breast cancer is the fifth leading cause of cancer death globally. In this retrospective study, we investigated the effects of the diagnosis-to-first-treatment interval (DFTI) and other related factors on cancer-specific survival in patients with breast cancer. We included 49,426 patients newly diagnosed as having breast cancer during 2011–2017. The Cox proportional hazards model was used to analyze the hazard ratio (HR) for mortality with various DFTIs; the HRs of the 31–60-, 61–90-, and ≥ 91-day DFTI groups did not differ significantly compared with the reference group (DFTI ≤ 30 days). After stratifying the patients according to initial tumor stage and age, we found that patients aged 55–64 and ≥ 65 years with stage II breast cancer treated ≥ 91 days after diagnosis had a 3.34- and 2.93-fold higher mortality risk (95% confidence intervals [CIs] 1.29–8.69 and 1.06–8.10, respectively). Patients aged ≥ 65 years with stage IV breast cancer treated within 61–90 or ≥ 91 days after diagnosis had a 7.14- and 34.78-fold higher mortality risk (95% CIs 1.28–39.82 and 3.08–393.32, respectively). In conclusion, DFTI is associated with mortality in patients with stage II and IV breast cancer, especially at an older age. |
| first_indexed | 2024-04-11T08:03:48Z |
| format | Article |
| id | doaj.art-90aa4d7d5ef740e88475ab6eeb469e7e |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T08:03:48Z |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-90aa4d7d5ef740e88475ab6eeb469e7e2022-12-22T04:35:37ZengNature PortfolioScientific Reports2045-23222022-11-0112111010.1038/s41598-022-23683-yAssociation of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in TaiwanNai-Chen Shih0Pei-Tseng Kung1Wei-Yin Kuo2Wen-Chen Tsai3Department of Family Medicine, Taichung Veterans General HospitalDepartment of Healthcare Administration, Asia UniversityDepartment of Health Services Administration, China Medical UniversityDepartment of Health Services Administration, China Medical UniversityAbstract Breast cancer is the fifth leading cause of cancer death globally. In this retrospective study, we investigated the effects of the diagnosis-to-first-treatment interval (DFTI) and other related factors on cancer-specific survival in patients with breast cancer. We included 49,426 patients newly diagnosed as having breast cancer during 2011–2017. The Cox proportional hazards model was used to analyze the hazard ratio (HR) for mortality with various DFTIs; the HRs of the 31–60-, 61–90-, and ≥ 91-day DFTI groups did not differ significantly compared with the reference group (DFTI ≤ 30 days). After stratifying the patients according to initial tumor stage and age, we found that patients aged 55–64 and ≥ 65 years with stage II breast cancer treated ≥ 91 days after diagnosis had a 3.34- and 2.93-fold higher mortality risk (95% confidence intervals [CIs] 1.29–8.69 and 1.06–8.10, respectively). Patients aged ≥ 65 years with stage IV breast cancer treated within 61–90 or ≥ 91 days after diagnosis had a 7.14- and 34.78-fold higher mortality risk (95% CIs 1.28–39.82 and 3.08–393.32, respectively). In conclusion, DFTI is associated with mortality in patients with stage II and IV breast cancer, especially at an older age.https://doi.org/10.1038/s41598-022-23683-y |
| spellingShingle | Nai-Chen Shih Pei-Tseng Kung Wei-Yin Kuo Wen-Chen Tsai Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan Scientific Reports |
| title | Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan |
| title_full | Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan |
| title_fullStr | Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan |
| title_full_unstemmed | Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan |
| title_short | Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan |
| title_sort | association of treatment delay and stage with mortality in breast cancer a nationwide cohort study in taiwan |
| url | https://doi.org/10.1038/s41598-022-23683-y |
| work_keys_str_mv | AT naichenshih associationoftreatmentdelayandstagewithmortalityinbreastcanceranationwidecohortstudyintaiwan AT peitsengkung associationoftreatmentdelayandstagewithmortalityinbreastcanceranationwidecohortstudyintaiwan AT weiyinkuo associationoftreatmentdelayandstagewithmortalityinbreastcanceranationwidecohortstudyintaiwan AT wenchentsai associationoftreatmentdelayandstagewithmortalityinbreastcanceranationwidecohortstudyintaiwan |